Disease · GO_0007596
blood coagulation
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. blood coagulation. Diseases, record GO_0007596. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/GO_0007596
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EMICIZUMAB | CHEMBL3833393 | Antibody | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| FLUVASTATIN | CHEMBL2220442 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| WARFARIN | CHEMBL1464 | Small molecule | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BMS-986120 | CHEMBL4650381 | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| CLOPIDOGREL | CHEMBL1771 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LANABECESTAT | CHEMBL3989948 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIVAROXABAN | CHEMBL198362 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALTEPLASE | CHEMBL1201593 | Enzyme | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TICAGRELOR | CHEMBL398435 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets9
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| F10 | Coagulation factor IX and X | 2 | Coagulation factor IX and X other; Coagulation factor X inhibitor | Approval | https://conductscience.org/library/genes/2159 | Drugs and targets |
| P2RY12 | P2Y purinoceptor 12 | 2 | Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 negative allosteric modulator | Phase 1 | https://conductscience.org/library/genes/64805 | Drugs and targets |
| BACE1 | Beta-secretase 1 | 1 | Beta-secretase 1 inhibitor | Phase 1 | https://conductscience.org/library/genes/23621 | Drugs and targets |
| F9 | Coagulation factor IX and X | 1 | Coagulation factor IX and X other | Approval | https://conductscience.org/library/genes/2158 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| PLAT | Tissue-type plasminogen activator | 1 | Tissue-type plasminogen activator exogenous protein | Unknown | https://conductscience.org/library/genes/5327 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Phase 1 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| VKORC1 | Vitamin K epoxide reductase complex subunit 1 | 1 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | Phase 1 | https://conductscience.org/library/genes/79001 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00401414 | Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information | Not applicable | 344 | 2013-08-30 | Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation | WARFARIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00674297 | Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients | Phase 2 | 41 | 2018-05-01 | Antiphospholipid Syndrome | FLUVASTATIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02540668 | A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants | Phase 1 | 15 | 2019-03-25 | Healthy | LANABECESTAT, WARFARIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02225782 | Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function | Not applicable | 150 | Kidney Disease | ALTEPLASE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02439190 | CV004-007 Thrombosis Chamber Study | Phase 1 | 42 | Thrombosis | ASPIRIN, BMS-986120, CLOPIDOGREL | Its record names the disease | ClinicalTrials.gov | |
| NCT01829659 | The ACS Ethnicity Platelet Function Study | 4 | Acute Coronary Syndrome | TICAGRELOR | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT02058199 | Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery | Phase 1 | 2 | Gastric Bypass Status | RIVAROXABAN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 29269513 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/GO_0007596
GET https://conductscience.org/api/diseases/v1/GO_0007596/drugs